Last Updated: 2026

MeiraGTx

Rank#6372

Market Cap852.93M

CountryUnited States

Summary

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. MeiraGTx Holdings plc was incorporated in 2015 and is based in New York, New York.

History

MeiraGTx was founded in September 2015. The company quickly grew from a small three-person team to a fully integrated global gene therapy company with over 300 employees globally. The company has raised over $300 million in series A/B/C financing and has built an outstanding IP portfolio with 500+ issued and pending patents worldwide.

Mission

Our mission is to deliver transformative gene therapy treatments to address the genetic cause of diseases, offering new hope to patients

Vision

Transforming Care through Molecular Medicine

References

https://in.investing.com/equities/meiragtx-holdings

https://finance.yahoo.com/quote/MGTX/profile?p=MGTX

https://www.crunchbase.com/organization/meiragtx

https://companiesmarketcap.com/

https://www.meiragtx.com

Leadership team

Dr. Alexandria Forbes (CEO, Pres & Director)